| ATPase, Na+/K+ transporting, alpha 4 polypeptide |
TANNIC ACID |
ATPase, Na+/K+ |
95% |
1.335uM |
NoneNone |
View
|
| ATPase, Na+/K+ transporting, alpha 3 polypeptide |
TANNIC ACID |
ATPase, Na+/K+ |
95% |
1.335uM |
NoneNone |
View
|
| ATPase, Na+/K+ transporting, alpha 2 polypeptide |
TANNIC ACID |
ATPase, Na+/K+ |
95% |
1.335uM |
NoneNone |
View
|
| ATPase, Na+/K+ transporting, alpha 1 polypeptide |
TANNIC ACID |
ATPase, Na+/K+ |
95% |
1.335uM |
NoneNone |
View
|
| ATPase, Na+/K+ transporting, beta 1 polypeptide |
TANNIC ACID |
ATPase, Na+/K+ |
95% |
1.335uM |
NoneNone |
View
|
| ATPase, Na+/K+ transporting, beta 3 polypeptide |
TANNIC ACID |
ATPase, Na+/K+ |
95% |
1.335uM |
NoneNone |
View
|
| ATPase, Na+/K+ transporting, beta 2 polypeptide |
TANNIC ACID |
ATPase, Na+/K+ |
95% |
1.335uM |
NoneNone |
View
|
| ATPase, (Na+)/K+ transporting, beta 4 polypeptide |
TANNIC ACID |
ATPase, Na+/K+ |
95% |
1.335uM |
NoneNone |
View
|
| Cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase) |
CLOTRIMAZOLE |
CYP450-2C9 Inhibition |
95% |
.016uM |
NoneNone |
View
|
| cytochrome P450, family 2, subfamily C, polypeptide 9 |
CLOTRIMAZOLE |
CYP450-2C9 Inhibition |
95% |
.016uM |
NoneNone |
View
|
| 5-hydroxytryptamine (serotonin) receptor 2A |
AMIODARONE |
Serotonin 5-HT2A |
95% |
3.59uM |
1.026uM |
View
|
| cholinergic receptor, muscarinic 1 |
TROPICAMIDE |
Muscarinic M1 |
95% |
.281uM |
.068uM |
View
|
| v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) |
COLISTIN |
Protein Tyrosine Kinase, HER2 Receptor |
95% |
2.227uM |
NoneNone |
View
|
| v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) |
COLISTIN |
Protein Tyrosine Kinase, HER2 Receptor |
95% |
2.227uM |
NoneNone |
View
|
| 5-hydroxytryptamine (serotonin) receptor 1A |
TAMOXIFEN |
Serotonin 5-HT1A |
95% |
12.16uM |
6.949uM |
View
|
| FMS-like tyrosine kinase 1 |
2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN |
Vascular Endothelinal Growth Factor (VEGF) |
95% |
.00269uM |
.000697uM |
View
|
| fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor) |
2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN |
Vascular Endothelinal Growth Factor (VEGF) |
95% |
.00269uM |
.000697uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 1A |
SULOCTIDIL |
Serotonin 5-HT1A |
95% |
.5435uM |
.3106uM |
View
|
| protein kinase C, gamma |
PACLITAXEL |
Phorbol Ester |
19% |
NoneNone |
NoneNone |
View
|
| cholinergic receptor, muscarinic 5 |
PERHEXILINE |
Muscarinic M5 |
95% |
1.0932uM |
.7854uM |
View
|
| Cytochrom P450-2D6 monooxygenase |
THIORIDAZINE |
CYP450-2D6 Inhibition |
95% |
1.7726uM |
NoneNone |
View
|
| Cytochrom P450-2D6 monooxygenase |
PERHEXILINE |
CYP450-2D6 Inhibition |
95% |
.9408uM |
NoneNone |
View
|
| adrenergic receptor, alpha 2a |
SULOCTIDIL |
Adrenergic alpha2A |
95% |
2.0232uM |
.7587uM |
View
|
| opioid receptor, sigma 1 |
CINNARIZINE |
Sigma1 |
95% |
.04uM |
.017uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 2C |
TERFENADINE |
Serotonin 5-HT2C |
95% |
1.231uM |
.645uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 2B |
PROPAFENONE |
Serotonin 5-HT2B |
95% |
.092uM |
.058uM |
View
|
| epidermal growth factor receptor |
IODOQUINOL |
Protein Tyrosine Kinase, EGF Receptor |
95% |
1.889uM |
NoneNone |
View
|
| cholinergic receptor, muscarinic 3 |
DESLORATADINE |
Muscarinic M3 |
95% |
.446uM |
.095uM |
View
|
| cholinergic receptor, muscarinic 2 |
DIMENHYDRINATE |
Muscarinic M2 |
95% |
.461uM |
.164uM |
View
|
| cholinergic receptor, muscarinic 3 |
DIMENHYDRINATE |
Muscarinic M3 |
95% |
.447uM |
.095uM |
View
|
| arachidonate 15-lipoxygenase, second type |
ISOPRENALINE |
Lipoxygenase 15-LO |
95% |
1.77uM |
NoneNone |
View
|
| arachidonate 15-lipoxygenase |
ISOPRENALINE |
Lipoxygenase 15-LO |
95% |
1.77uM |
NoneNone |
View
|
| arachidonate 15-lipoxygenase |
ISOPRENALINE |
Lipoxygenase 15-LO |
95% |
1.77uM |
NoneNone |
View
|
| calcium channel, voltage-dependent, gamma subunit 8 |
FLUNARIZINE |
Calcium Channel Type L, Phenylalkylamine |
95% |
.177uM |
.172uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 7 |
FLUNARIZINE |
Calcium Channel Type L, Phenylalkylamine |
95% |
.177uM |
.172uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 6 |
FLUNARIZINE |
Calcium Channel Type L, Phenylalkylamine |
95% |
.177uM |
.172uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 5 |
FLUNARIZINE |
Calcium Channel Type L, Phenylalkylamine |
95% |
.177uM |
.172uM |
View
|
| sodium channel, voltage-gated, type II, alpha 2 |
PROPARACAINE |
Sodium Channel, Site 2 |
94% |
1.407uM |
1.283uM |
View
|
| sodium channel, voltage-gated, type I, beta |
PROPARACAINE |
Sodium Channel, Site 2 |
94% |
1.407uM |
1.283uM |
View
|
| sodium channel, voltage-gated, type I, alpha |
PROPARACAINE |
Sodium Channel, Site 2 |
94% |
1.407uM |
1.283uM |
View
|
| solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
CLOPIDOGREL |
Serotonin Transporter |
94% |
.562uM |
.299uM |
View
|
| epidermal growth factor receptor |
CLOMIPHENE |
Protein Tyrosine Kinase, EGF Receptor |
94% |
1.05uM |
NoneNone |
View
|
| cholinergic receptor, muscarinic 5 |
CLOMIPHENE |
Muscarinic M5 |
94% |
1.771uM |
1.272uM |
View
|
| dopamine receptor D1A |
DROPERIDOL |
Dopamine D1 |
94% |
1.092uM |
.546uM |
View
|
| dopamine receptor D1A |
HALOPROGIN |
Dopamine D1 |
94% |
.563uM |
.282uM |
View
|
| adrenergic receptor, beta 1 |
S-(-)-PROPRANOLOL |
Adrenergic beta1 |
94% |
.001908uM |
.001102uM |
View
|
| adrenergic, beta-1-, receptor |
S-(-)-PROPRANOLOL |
Adrenergic beta1 |
94% |
.001908uM |
.001102uM |
View
|
| adrenergic receptor, beta 3 |
S-(-)-PROPRANOLOL |
Adrenergic beta3 |
94% |
.165uM |
.124uM |
View
|
| sodium channel associated protein 1 |
NORTRIPTYLINE |
Sodium Channel, Site 2 |
94% |
1.929uM |
1.759uM |
View
|
| sodium channel associated protein 2 |
NORTRIPTYLINE |
Sodium Channel, Site 2 |
94% |
1.929uM |
1.759uM |
View
|
| sodium channel, voltage-gated, type III, beta |
NORTRIPTYLINE |
Sodium Channel, Site 2 |
94% |
1.929uM |
1.759uM |
View
|
| sodium channel, voltage-gated, type I, alpha |
NORTRIPTYLINE |
Sodium Channel, Site 2 |
94% |
1.929uM |
1.759uM |
View
|
| sodium channel, voltage-gated, type IX, alpha |
NORTRIPTYLINE |
Sodium Channel, Site 2 |
94% |
1.929uM |
1.759uM |
View
|
| sodium channel, voltage-gated, type VII, alpha |
NORTRIPTYLINE |
Sodium Channel, Site 2 |
94% |
1.929uM |
1.759uM |
View
|
| amiloride-sensitive cation channel 5, intestinal |
NORTRIPTYLINE |
Sodium Channel, Site 2 |
94% |
1.929uM |
1.759uM |
View
|
| sodium channel, voltage-gated, type III, beta |
NORTRIPTYLINE |
Sodium Channel, Site 2 |
94% |
1.929uM |
1.759uM |
View
|
| sodium channel, voltage-gated, type VIII, alpha polypeptide |
NORTRIPTYLINE |
Sodium Channel, Site 2 |
94% |
1.929uM |
1.759uM |
View
|
| sodium channel, voltage-gated, type XI, alpha |
NORTRIPTYLINE |
Sodium Channel, Site 2 |
94% |
1.929uM |
1.759uM |
View
|
| sodium channel, voltage-gated, type I, beta |
NORTRIPTYLINE |
Sodium Channel, Site 2 |
94% |
1.929uM |
1.759uM |
View
|
| sodium channel, voltage-gated, type 10, alpha polypeptide |
NORTRIPTYLINE |
Sodium Channel, Site 2 |
94% |
1.929uM |
1.759uM |
View
|
| sodium channel, voltage-gated, type IV, alpha polypeptide |
NORTRIPTYLINE |
Sodium Channel, Site 2 |
94% |
1.929uM |
1.759uM |
View
|
| sodium channel, voltage-gated, type V, alpha polypeptide |
NORTRIPTYLINE |
Sodium Channel, Site 2 |
94% |
1.929uM |
1.759uM |
View
|
| sodium channel, voltage-gated, type II, beta |
NORTRIPTYLINE |
Sodium Channel, Site 2 |
94% |
1.929uM |
1.759uM |
View
|
| sodium channel, nonvoltage-gated 1 alpha |
NORTRIPTYLINE |
Sodium Channel, Site 2 |
94% |
1.929uM |
1.759uM |
View
|
| protein kinase C, alpha |
PACLITAXEL |
Phorbol Ester |
19% |
NoneNone |
NoneNone |
View
|
| sodium channel, nonvoltage-gated 1 gamma |
NORTRIPTYLINE |
Sodium Channel, Site 2 |
94% |
1.929uM |
1.759uM |
View
|
| sodium channel, nonvoltage-gated 1 beta |
NORTRIPTYLINE |
Sodium Channel, Site 2 |
94% |
1.929uM |
1.759uM |
View
|
| sodium channel, voltage-gated, type 2, alpha 1 polypeptide |
NORTRIPTYLINE |
Sodium Channel, Site 2 |
94% |
1.929uM |
1.759uM |
View
|
| sodium channel, voltage-gated, type XI, alpha |
NORTRIPTYLINE |
Sodium Channel, Site 2 |
94% |
1.929uM |
1.759uM |
View
|
| sodium channel, nonvoltage-gated 1, gamma |
NORTRIPTYLINE |
Sodium Channel, Site 2 |
94% |
1.929uM |
1.759uM |
View
|
| sodium channel, nonvoltage-gated 1, delta |
NORTRIPTYLINE |
Sodium Channel, Site 2 |
94% |
1.929uM |
1.759uM |
View
|
| tachykinin receptor 2 |
SAQUINAVIR |
Tachykinin NK2 |
94% |
6.214uM |
2.071uM |
View
|
| cytochrome P450, family 3, subfamily a, polypeptide 13 |
RITONAVIR |
CYP450-3A4 Inhibition |
94% |
.016uM |
NoneNone |
View
|
| 5-hydroxytryptamine (serotonin) receptor 2B |
OXICONAZOLE |
Serotonin 5-HT2B |
94% |
4.6064uM |
2.9314uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 2B |
OXYBUTYNIN |
Serotonin 5-HT2B |
94% |
.792uM |
.504uM |
View
|
| thromboxane A synthase 1 |
OXICONAZOLE |
Thromboxane Synthetase |
94% |
.6174uM |
NoneNone |
View
|
| thromboxane A synthase 1 (platelet, cytochrome P450, family 5, subfamily A) |
OXICONAZOLE |
Thromboxane Synthetase |
94% |
.6174uM |
NoneNone |
View
|
| 5-hydroxytryptamine (serotonin) receptor 2C |
OXYMETAZOLINE |
Serotonin 5-HT2C |
94% |
.578uM |
.303uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 2C |
ORPHENADRINE |
Serotonin 5-HT2C |
94% |
.534uM |
.28uM |
View
|
| adrenergic receptor, beta 1 |
ACEBUTOLOL |
Adrenergic beta1 |
94% |
.731uM |
.422uM |
View
|
| adrenergic, beta-1-, receptor |
ACEBUTOLOL |
Adrenergic beta1 |
94% |
.731uM |
.422uM |
View
|
| adrenergic receptor, beta 3 |
EBASTINE |
Adrenergic beta3 |
94% |
2.5455uM |
1.9091uM |
View
|
| dopamine receptor 2 |
LEVOSULPIRIDE |
Dopamine D2L |
94% |
.128uM |
.043uM |
View
|
| cholinergic receptor, muscarinic 2 |
EBASTINE |
Muscarinic M2 |
94% |
.786uM |
.2795uM |
View
|
| adrenergic receptor, alpha 2a |
PROMETHAZINE |
Adrenergic alpha2A |
94% |
.681uM |
.256uM |
View
|
| opioid receptor, sigma 1 |
PROPARACAINE |
Sigma1 |
94% |
.238uM |
.1uM |
View
|
| dopamine receptor D3 |
RALOXIFENE |
Dopamine D3 |
94% |
1.565uM |
.531uM |
View
|
| sodium channel, voltage-gated, type IV, beta |
PROPARACAINE |
Sodium Channel, Site 2 |
94% |
1.407uM |
1.283uM |
View
|
| sodium channel associated protein 1 |
PROPARACAINE |
Sodium Channel, Site 2 |
94% |
1.407uM |
1.283uM |
View
|
| sodium channel associated protein 2 |
PROPARACAINE |
Sodium Channel, Site 2 |
94% |
1.407uM |
1.283uM |
View
|
| sodium channel, voltage-gated, type III, beta |
PROPARACAINE |
Sodium Channel, Site 2 |
94% |
1.407uM |
1.283uM |
View
|
| sodium channel, voltage-gated, type I, alpha |
PROPARACAINE |
Sodium Channel, Site 2 |
94% |
1.407uM |
1.283uM |
View
|
| sodium channel, voltage-gated, type IX, alpha |
PROPARACAINE |
Sodium Channel, Site 2 |
94% |
1.407uM |
1.283uM |
View
|
| sodium channel, voltage-gated, type VII, alpha |
PROPARACAINE |
Sodium Channel, Site 2 |
94% |
1.407uM |
1.283uM |
View
|
| amiloride-sensitive cation channel 5, intestinal |
PROPARACAINE |
Sodium Channel, Site 2 |
94% |
1.407uM |
1.283uM |
View
|
| sodium channel, voltage-gated, type III, beta |
PROPARACAINE |
Sodium Channel, Site 2 |
94% |
1.407uM |
1.283uM |
View
|
| sodium channel, voltage-gated, type VIII, alpha polypeptide |
PROPARACAINE |
Sodium Channel, Site 2 |
94% |
1.407uM |
1.283uM |
View
|
| sodium channel, voltage-gated, type XI, alpha |
PROPARACAINE |
Sodium Channel, Site 2 |
94% |
1.407uM |
1.283uM |
View
|
| sodium channel, voltage-gated, type I, beta |
PROPARACAINE |
Sodium Channel, Site 2 |
94% |
1.407uM |
1.283uM |
View
|
| sodium channel, voltage-gated, type 10, alpha polypeptide |
PROPARACAINE |
Sodium Channel, Site 2 |
94% |
1.407uM |
1.283uM |
View
|
| sodium channel, voltage-gated, type IV, alpha polypeptide |
PROPARACAINE |
Sodium Channel, Site 2 |
94% |
1.407uM |
1.283uM |
View
|
| sodium channel, voltage-gated, type V, alpha polypeptide |
PROPARACAINE |
Sodium Channel, Site 2 |
94% |
1.407uM |
1.283uM |
View
|
| sodium channel, voltage-gated, type II, beta |
PROPARACAINE |
Sodium Channel, Site 2 |
94% |
1.407uM |
1.283uM |
View
|
| sodium channel, nonvoltage-gated 1 alpha |
PROPARACAINE |
Sodium Channel, Site 2 |
94% |
1.407uM |
1.283uM |
View
|
| sodium channel, nonvoltage-gated 1 gamma |
PROPARACAINE |
Sodium Channel, Site 2 |
94% |
1.407uM |
1.283uM |
View
|
| sodium channel, nonvoltage-gated 1 beta |
PROPARACAINE |
Sodium Channel, Site 2 |
94% |
1.407uM |
1.283uM |
View
|
| sodium channel, voltage-gated, type 2, alpha 1 polypeptide |
PROPARACAINE |
Sodium Channel, Site 2 |
94% |
1.407uM |
1.283uM |
View
|
| sodium channel, voltage-gated, type XI, alpha |
PROPARACAINE |
Sodium Channel, Site 2 |
94% |
1.407uM |
1.283uM |
View
|
| sodium channel, nonvoltage-gated 1, gamma |
PROPARACAINE |
Sodium Channel, Site 2 |
94% |
1.407uM |
1.283uM |
View
|
| sodium channel, nonvoltage-gated 1, delta |
PROPARACAINE |
Sodium Channel, Site 2 |
94% |
1.407uM |
1.283uM |
View
|
| protein kinase C, epsilon |
FAMOTIDINE |
Phorbol Ester |
3% |
NoneNone |
NoneNone |
View
|
| sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) |
PROPARACAINE |
Sodium Channel, Site 2 |
94% |
1.407uM |
1.283uM |
View
|
| sodium channel, nonvoltage-gated 1 alpha |
PROPARACAINE |
Sodium Channel, Site 2 |
94% |
1.407uM |
1.283uM |
View
|
| sodium channel, voltage-gated, type X, alpha |
PROPARACAINE |
Sodium Channel, Site 2 |
94% |
1.407uM |
1.283uM |
View
|
| gamma-aminobutyric acid A receptor, gamma 1 |
ZALEPLON |
GABAA, Benzodiazepine, Central |
94% |
.412uM |
.336uM |
View
|
| gamma-aminobutyric acid A receptor, pi |
ZALEPLON |
GABAA, Benzodiazepine, Central |
94% |
.412uM |
.336uM |
View
|
| AT hook, DNA binding motif, containing 1 (DBSS) |
ZALEPLON |
GABAA, Benzodiazepine, Central |
94% |
.412uM |
.336uM |
View
|
| gamma-aminobutyric acid A receptor, theta |
ZALEPLON |
GABAA, Benzodiazepine, Central |
94% |
.412uM |
.336uM |
View
|
| gamma-aminobutyric acid A receptor, gamma 2 |
ZALEPLON |
GABAA, Benzodiazepine, Central |
94% |
.412uM |
.336uM |
View
|
| gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 6 |
ZALEPLON |
GABAA, Benzodiazepine, Central |
94% |
.412uM |
.336uM |
View
|
| gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 5 |
ZALEPLON |
GABAA, Benzodiazepine, Central |
94% |
.412uM |
.336uM |
View
|
| gamma-aminobutyric acid A receptor, alpha 2 |
ZALEPLON |
GABAA, Benzodiazepine, Central |
94% |
.412uM |
.336uM |
View
|
| gamma-aminobutyric acid A receptor, alpha 1 |
ZALEPLON |
GABAA, Benzodiazepine, Central |
94% |
.412uM |
.336uM |
View
|
| gamma-aminobutyric acid (GABA-C) receptor, subunit rho 2 |
ZALEPLON |
GABAA, Benzodiazepine, Central |
94% |
.412uM |
.336uM |
View
|
| gamma-aminobutyric acid (GABA-C) receptor, subunit rho 1 |
ZALEPLON |
GABAA, Benzodiazepine, Central |
94% |
.412uM |
.336uM |
View
|
| gamma-aminobutyric acid A receptor, delta |
ZALEPLON |
GABAA, Benzodiazepine, Central |
94% |
.412uM |
.336uM |
View
|
| gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 3 |
ZALEPLON |
GABAA, Benzodiazepine, Central |
94% |
.412uM |
.336uM |
View
|
| adrenergic receptor, alpha 2b |
TRAZODONE |
Adrenergic alpha2B |
94% |
.389uM |
.178uM |
View
|
| cholinergic receptor, muscarinic 2 |
GENTIAN VIOLET |
Muscarinic M2 |
94% |
1.43uM |
.508uM |
View
|
| adrenergic receptor, alpha 2b |
GENTIAN VIOLET |
Adrenergic alpha2B |
94% |
1.258uM |
.574uM |
View
|
| adrenergic receptor, alpha 1d (Non-specific probe) |
BROMOCRIPTINE |
Adrenergic alpha1D |
94% |
.03uM |
.015uM |
View
|
| adrenergic receptor, alpha 2b |
BROMOCRIPTINE |
Adrenergic alpha2C |
94% |
.52uM |
.076uM |
View
|
| adrenergic receptor, alpha 2c (Non-specific probe) |
BROMOCRIPTINE |
Adrenergic alpha2C |
94% |
.52uM |
.076uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 2C |
VERAPAMIL |
Serotonin 5-HT2C |
94% |
.297uM |
.155uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 2C |
CITALOPRAM |
Serotonin 5-HT2C |
94% |
.297uM |
.156uM |
View
|
| cytochrome P450, family 3, subfamily a, polypeptide 13 |
INDINAVIR |
CYP450-3A4 Inhibition |
94% |
.4uM |
NoneNone |
View
|
| calcium channel, voltage-dependent, beta 4 subunit |
LOPERAMIDE |
Calcium Channel Type L, Benzothiazepine |
94% |
.221uM |
.196uM |
View
|
| calcium channel, voltage-dependent, beta 3 subunit |
LOPERAMIDE |
Calcium Channel Type L, Benzothiazepine |
94% |
.221uM |
.196uM |
View
|
| calcium channel, voltage-dependent, beta 2 subunit |
LOPERAMIDE |
Calcium Channel Type L, Benzothiazepine |
94% |
.221uM |
.196uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1S subunit |
LOPERAMIDE |
Calcium Channel Type L, Benzothiazepine |
94% |
.221uM |
.196uM |
View
|
| calcium channel, voltage-dependent, alpha 1F subunit |
LOPERAMIDE |
Calcium Channel Type L, Benzothiazepine |
94% |
.221uM |
.196uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1D subunit |
LOPERAMIDE |
Calcium Channel Type L, Benzothiazepine |
94% |
.221uM |
.196uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1C subunit |
LOPERAMIDE |
Calcium Channel Type L, Benzothiazepine |
94% |
.221uM |
.196uM |
View
|
| calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
LOPERAMIDE |
Calcium Channel Type L, Benzothiazepine |
94% |
.221uM |
.196uM |
View
|
| calcium channel, voltage-dependent, beta 1 subunit |
LOPERAMIDE |
Calcium Channel Type L, Benzothiazepine |
94% |
.221uM |
.196uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 4 |
FLUNARIZINE |
Calcium Channel Type L, Phenylalkylamine |
95% |
.177uM |
.172uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 3 |
FLUNARIZINE |
Calcium Channel Type L, Phenylalkylamine |
95% |
.177uM |
.172uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 2 |
FLUNARIZINE |
Calcium Channel Type L, Phenylalkylamine |
95% |
.177uM |
.172uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 1 |
FLUNARIZINE |
Calcium Channel Type L, Phenylalkylamine |
95% |
.177uM |
.172uM |
View
|
| calcium channel, voltage-dependent, beta 4 subunit |
FLUNARIZINE |
Calcium Channel Type L, Phenylalkylamine |
95% |
.177uM |
.172uM |
View
|
| calcium channel, voltage-dependent, beta 3 subunit |
FLUNARIZINE |
Calcium Channel Type L, Phenylalkylamine |
95% |
.177uM |
.172uM |
View
|
| calcium channel, voltage-dependent, beta 2 subunit |
FLUNARIZINE |
Calcium Channel Type L, Phenylalkylamine |
95% |
.177uM |
.172uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1S subunit |
FLUNARIZINE |
Calcium Channel Type L, Phenylalkylamine |
95% |
.177uM |
.172uM |
View
|
| calcium channel, voltage-dependent, alpha 1F subunit |
FLUNARIZINE |
Calcium Channel Type L, Phenylalkylamine |
95% |
.177uM |
.172uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1D subunit |
FLUNARIZINE |
Calcium Channel Type L, Phenylalkylamine |
95% |
.177uM |
.172uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1C subunit |
FLUNARIZINE |
Calcium Channel Type L, Phenylalkylamine |
95% |
.177uM |
.172uM |
View
|
| calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
FLUNARIZINE |
Calcium Channel Type L, Phenylalkylamine |
95% |
.177uM |
.172uM |
View
|
| calcium channel, voltage-dependent, beta 1 subunit |
FLUNARIZINE |
Calcium Channel Type L, Phenylalkylamine |
95% |
.177uM |
.172uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1E subunit |
FLUNARIZINE |
Calcium Channel Type L, Phenylalkylamine |
95% |
.177uM |
.172uM |
View
|
| calcium channel, voltage-dependent, N type, alpha 1B subunit |
FLUNARIZINE |
Calcium Channel Type L, Phenylalkylamine |
95% |
.177uM |
.172uM |
View
|
| calcium channel, voltage-dependent, alpha2/delta subunit 1 |
FLUNARIZINE |
Calcium Channel Type L, Phenylalkylamine |
95% |
.177uM |
.172uM |
View
|
| Cytochrom P450-2C19 monooxygenase |
NOVARTIS P-38 INHIBITOR |
CYP450-2C19 Inhibition |
95% |
.3uM |
NoneNone |
View
|
| acetylcholinesterase (YT blood group) |
BERBERINE CHLORIDE |
Acetylcholinesterase |
95% |
.774uM |
NoneNone |
View
|
| collagen-like tail subunit (single strand of homotrimer) of asymmetric acetylcholinesterase |
BERBERINE CHLORIDE |
Acetylcholinesterase |
95% |
.774uM |
NoneNone |
View
|
| acetylcholinesterase |
BERBERINE CHLORIDE |
Acetylcholinesterase |
95% |
.774uM |
NoneNone |
View
|
| solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
DOBUTAMINE |
Adrenergic, Norepinephrine Transporter |
95% |
.383uM |
.38uM |
View
|
| adrenergic receptor, alpha 1d (Non-specific probe) |
MAPROTILINE |
Adrenergic alpha1D |
95% |
.397uM |
.195uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 2C |
BENZTROPINE |
Serotonin 5-HT2C |
95% |
.061uM |
.032uM |
View
|
| dopamine receptor D1A |
MAPROTILINE |
Dopamine D1 |
95% |
.373uM |
.187uM |
View
|
| adrenergic receptor, beta 2 |
LISURIDE |
Adrenergic beta2 |
95% |
.041uM |
.029uM |
View
|
| mu-opioid receptor MOR |
SPIRADOLINE |
Opiate mu |
95% |
.234uM |
.095uM |
View
|
| adrenergic receptor, alpha 2a |
CLONIDINE |
Imidazoline I2, Central |
95% |
.064uM |
.043uM |
View
|
| adrenergic receptor, alpha 2c (Non-specific probe) |
CLONIDINE |
Imidazoline I2, Central |
95% |
.064uM |
.043uM |
View
|
| dopamine receptor 2 |
LISURIDE |
Dopamine D2L |
95% |
.00286uM |
.000953uM |
View
|
| dopamine receptor 2 |
DIHYDROERGOCRISTINE MESYLATE |
Dopamine D2L |
95% |
.001474uM |
.000491uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 2C |
DIHYDROERGOCRISTINE MESYLATE |
Serotonin 5-HT2C |
95% |
.239uM |
.125uM |
View
|
| cholinergic receptor, muscarinic 3 |
PROMAZINE |
Muscarinic M3 |
95% |
.416uM |
.088uM |
View
|
| sodium channel, nonvoltage-gated 1 beta |
TERBINAFINE |
Sodium Channel, Site 2 |
95% |
1.4026uM |
1.2795uM |
View
|
| sodium channel, voltage-gated, type 2, alpha 1 polypeptide |
TERBINAFINE |
Sodium Channel, Site 2 |
95% |
1.4026uM |
1.2795uM |
View
|
| sodium channel, voltage-gated, type XI, alpha |
TERBINAFINE |
Sodium Channel, Site 2 |
95% |
1.4026uM |
1.2795uM |
View
|
| sodium channel, nonvoltage-gated 1, gamma |
TERBINAFINE |
Sodium Channel, Site 2 |
95% |
1.4026uM |
1.2795uM |
View
|
| sodium channel, nonvoltage-gated 1, delta |
TERBINAFINE |
Sodium Channel, Site 2 |
95% |
1.4026uM |
1.2795uM |
View
|
| sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) |
TERBINAFINE |
Sodium Channel, Site 2 |
95% |
1.4026uM |
1.2795uM |
View
|
| sodium channel, nonvoltage-gated 1 alpha |
TERBINAFINE |
Sodium Channel, Site 2 |
95% |
1.4026uM |
1.2795uM |
View
|
| sodium channel, voltage-gated, type X, alpha |
TERBINAFINE |
Sodium Channel, Site 2 |
95% |
1.4026uM |
1.2795uM |
View
|
| sodium channel, voltage-gated, type IX, alpha |
TERBINAFINE |
Sodium Channel, Site 2 |
95% |
1.4026uM |
1.2795uM |
View
|
| sodium channel, voltage gated, type VIII, alpha |
TERBINAFINE |
Sodium Channel, Site 2 |
95% |
1.4026uM |
1.2795uM |
View
|
| sodium channel, voltage-gated, type VII, alpha |
TERBINAFINE |
Sodium Channel, Site 2 |
95% |
1.4026uM |
1.2795uM |
View
|
| sodium channel, voltage-gated, type IX, alpha |
PROPARACAINE |
Sodium Channel, Site 2 |
94% |
1.407uM |
1.283uM |
View
|
| sodium channel, voltage gated, type VIII, alpha |
PROPARACAINE |
Sodium Channel, Site 2 |
94% |
1.407uM |
1.283uM |
View
|
| sodium channel, voltage-gated, type VII, alpha |
PROPARACAINE |
Sodium Channel, Site 2 |
94% |
1.407uM |
1.283uM |
View
|
| sodium channel, voltage-gated, type V, alpha (long QT syndrome 3) |
PROPARACAINE |
Sodium Channel, Site 2 |
94% |
1.407uM |
1.283uM |
View
|
| sodium channel, voltage-gated, type IV, beta |
PROPARACAINE |
Sodium Channel, Site 2 |
94% |
1.407uM |
1.283uM |
View
|
| sodium channel, voltage-gated, type IV, alpha |
PROPARACAINE |
Sodium Channel, Site 2 |
94% |
1.407uM |
1.283uM |
View
|
| sodium channel, voltage-gated, type III, alpha |
PROPARACAINE |
Sodium Channel, Site 2 |
94% |
1.407uM |
1.283uM |
View
|
| sodium channel, voltage-gated, type II, beta |
PROPARACAINE |
Sodium Channel, Site 2 |
94% |
1.407uM |
1.283uM |
View
|
| protein kinase C, gamma |
FAMOTIDINE |
Phorbol Ester |
3% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, beta 1 subunit |
CARVEDILOL |
Calcium Channel Type L, Phenylalkylamine |
95% |
.389uM |
.378uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1E subunit |
CARVEDILOL |
Calcium Channel Type L, Phenylalkylamine |
95% |
.389uM |
.378uM |
View
|
| calcium channel, voltage-dependent, N type, alpha 1B subunit |
CARVEDILOL |
Calcium Channel Type L, Phenylalkylamine |
95% |
.389uM |
.378uM |
View
|